Psoriatic arthritis is a potentially serious disorder leading to a significant disability in 20–30 % of patients. Pharmacological treatment is limited to non-steroidal anti-inflammatory drugs, sulfasalazine, methotrexate and cyclosporine A. In contrast to rheumatoid arthritis, there has not been any biological agent registered in the Czech Republic yet. The registration is expected in 2005. Indication criteria and methods of monitoring of biological treatment before its assumed registration in 2005 are summarized in the present paper.

        Key words: psoriatic arthritis, biologic treatment, standard methods